NEWTON BIOCAPITAL
Newton Biocapital is a Venture Capital Fund incorporated in Belgium, focused on financing biotech and life science projects in the "core of Europe" (B, NL, D, F) and Japan for the prevention and treatment of chronic diseases. Their approach as lead investor is to support promising start-up projects as well as neglected or undervalued late-stage projects, in order to mitigate the risks and to create investor value. The leadership team consi.sts of specialists with long-standing management and investor experience who coach bio-entrepreneurs through the development stages of their projects.
NEWTON BIOCAPITAL
Industry:
Finance Financial Services Venture Capital
Founded:
2017-01-01
Status:
Active
Technology used in webpage:
Japanese Yen Combell
Similar Organizations
Felix Capital
Felix Capital is a venture fund that focuses on digital commerce, digital media, and information technology companies.
Section 32
Section 32 is a venture capital fund that invests at the cutting edge of technology, healthcare, and life sciences.
Current Employees Featured
Founder
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2021-06-24 | NeuVasQ | Newton Biocapital investment in Series A - NeuVasQ | 20 M EUR |
| 2021-05-26 | EditForce | Newton Biocapital investment in Venture Round - EditForce | 800 M JPY |
| 2021-02-24 | DeuterOncology | Newton Biocapital investment in Seed Round - DeuterOncology | N/A |
| 2020-11-30 | Perseus Proteomics | Newton Biocapital investment in Venture Round - Perseus Proteomics | 140 M JPY |
| 2020-11-04 | AbolerIS Pharma | Newton Biocapital investment in Seed Round - AbolerIS Pharma | 2.5 M EUR |
| 2020-07-30 | J-Pharma | Newton Biocapital investment in Series D - J-Pharma | 1.75 M JPY |
| 2019-11-06 | Acticor Biotech | Newton Biocapital investment in Series B - Acticor Biotech | 7 M EUR |
| 2019-03-01 | EditForce | Newton Biocapital investment in Series B - EditForce | 870 M JPY |
| 2018-10-17 | Acticor Biotech | Newton Biocapital investment in Series B - Acticor Biotech | 15.3 M EUR |
| 2018-10-16 | Sequana Medical | Newton Biocapital investment in Series D - Sequana Medical | 8.5 M EUR |
More informations about "Newton Biocapital"
Newton Biocapital - Life Sciences Investments
Newton Biocapital announces its first investment in Japan from its โNewton Biocapital Partners IIโ fund to Japanese drug discovery startup, Tensegrity Pharma. Read more. 14th November 2024.See details»
About | Newton Biocapital - Life Sciences Investments
Newton Biocapitalโs investment approach is based on three core pillars: Thorough selection. We identify innovative solutions to chronic health conditions where the burden to both patients and reimbursement systems is high. Drawing on our โฆSee details»
Newton Biocapital - Crunchbase Investor Profile
Newton Biocapital is a Venture Capital Fund incorporated in Belgium, focused on financing biotech and life science projects in the "core of Europe" (B, NL, D, F) and Japan for the prevention and treatment of chronic diseases. Their โฆSee details»
Newton Biocapital - Investments, Portfolio & Company Exits
Newton Biocapital 's most notable exits include Acticor Biotech, ... Which industries has this organization had the most exits in? Show . Acticor Biotech Acticor Biotech is a โฆSee details»
Newton Biocapital - YouTube
Newton Biocapital is a VC firm focusing on early-stage Life Sciences companies targeting chronic health diseases. Our diversified team of experts and our presence in Japan/Europe enable us โฆSee details»
Newton BioCapital | Institution Profile - Private Equity International
Newton BioCapital. News, insights, analysis and data. Newton BioCapital overview. Newton BioCapital is a Brussels-based venture capital business that was established in 2017. The firm โฆSee details»
Newton Biocapital - teaserclub.com
It targets both promising start-ups and neglected or undervalued late-stage projects, aiming to mitigate risks while creating value for investors. Newton Biocapital's leadership team โฆSee details»
Newton Biocapital Investor Information - Funding, Portfolio โฆ
Newton Biocapital is a venture capital fund that invests in early-stage biotech and deep tech companies, focusing on chronic health conditions. With a presence in Japan and Europe, the โฆSee details»
Newton Biocapital
SANTERO announces a โฌ8 million Series A funding round led by Newton Biocapital to develop novel antibiotics in the fight against antimicrobial resistance. Read more. 31st 5ๆ 2023. โฆSee details»
Newton Biocapital - hub.waveup.com
Newton Biocapital is a Brussels-based venture capital firm with a strong presence in both Europe and Japan, focusing exclusively on the life sciencesSee details»
Newton BioCapital investment portfolio - PitchBook
Newton BioCapital's latest investment was on 13-Nov-2024 in Tensegrity Pharma, a company within the Drug Discovery industry. Data Transparency. Meet our data hygiene team. Discover โฆSee details»
Newton Biocapital - Funding, Financials, Valuation & Investors
Newton Biocapital has raised 2 funds, their latest being NBC II. This fund was announced on Feb 15, 2022 and raised a total of . obfuscated. obfuscated. Announced Date . Fund Name . โฆSee details»
Newton Biocapital VC Fund Leads Investment Wave in Japanese โฆ
Feb 18, 2022 Newton Biocapital invests in European and Japanese companies tackling aging-related chronic diseases including cancer and metabolic diseases. In 2017, Newton Biocapital โฆSee details»
Newton Biocapital launches a new fund with initial capital ... - BioVox
Brussels, Belgium, 15 February 2022 โ Newton Biocapital (โNewtonโ), a life sciences investor, announces the launch of its new fund (NBC II). As with NBC I, NBC II will focus on supporting โฆSee details»
Newton Biocapital - Tech Stack, Apps, Patents & Trademarks
Mar 10, 2025 Newton Biocapital is a venture capital investment fund that invests in the life sciences sector with a specialization in chronic diseases. New. Resources. Advanced Search. โฆSee details»
We are delighted toโฆ | Newton Biocapital - Life Sciences โฆ
This discussion aimed to further support Japan's life sciences ecosystem, and we, Newton Biocapital, are deeply honoured to have been invited to such a significant event. The insights โฆSee details»
Newton Biocapital II - VLAIO
Feb 5, 2025 Newton Biocapital investeert tussen โฌ 1 en 10 miljoen in bedrijven die oplossingen ontwikkelen voor de preventie en de behandeling van chronische ziekten (life sciences: โฆSee details»
Novel antibiotics in the fight against antimicrobial resistance
Jun 12, 2023 Newton Biocapital (NBC), a venture capital firm focused on investing and growing early-stage life sciences companies in Europe and Japan targeting chronic health conditions, โฆSee details»
EditForce, Inc.โฆ | Newton Biocapital - Life Sciences Investments
We applied for the Program with support and investment from Newton Biocapital as Certified VCs, and are now entitled to receive a subsidy from AMED for development of EF-210 since the โฆSee details»
Newton Biocapital invests in NeuVasQ: EUR 20 million Series A
Brussels, Belgium, 22 June 2021 โ Newton Biocapital I (โNewtonโ), a life sciences investment fund active in Europe and Japan focused on chronic diseases, has announced its investment โฆSee details»